ELK1 Promotes Epithelial-Mesenchymal Transition and the Progression of Lung Adenocarcinoma by Upregulating B7-H3

Table 1

ELK1 expression and clinicopathological characteristics of patients with LUAD.

Features		ELK1 expression			value
		Low	High
	90	41	49
Age (years)				0.045	0.832
≥60	45	20 (48.8)	25 (51.0)
<60	45	21 (51.2)	24 (49.0)
Gender				1.994	0.158
Male	49	19 (46.3)	30 (61.2)
Female	41	22 (53.7)	19 (38.8)
Smoking				0.231	0.631
Yes	46	23 (56.1)	25 (51.0)
No	44	18 (43.9)	24 (49.0)
Differentiation				0.637	0.425
Well/moderate	37	15 (36.6)	22 (44.9)
Poor	53	26 (63.4)	27 (55.1)
Tumor size				0.110	0.740
≤3cm	40	19 (46.3)	21 (42.9)
>3cm	50	22 (53.7)	28 (57.1)
Lymph node metastasis				9.545	0.002
Yes	51	16 (39.0)	35 (71.4)
No	39	25 (61.0)	14 (28.6)
TNM stage				5.443	0.020
I-II	54	30 (73.2)	24 (49.0)
III-IV	36	11 (26.8)	25 (51.0)